Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

277 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells.
Mologni L, Brussolo S, Ceccon M, Gambacorti-Passerini C. Mologni L, et al. PLoS One. 2012;7(12):e51449. doi: 10.1371/journal.pone.0051449. Epub 2012 Dec 5. PLoS One. 2012. PMID: 23227266 Free PMC article.
In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid.
Mologni L, Nielsen PE, Gambacorti-Passerini C. Mologni L, et al. Biochem Biophys Res Commun. 1999 Oct 22;264(2):537-43. doi: 10.1006/bbrc.1999.1548. Biochem Biophys Res Commun. 1999. PMID: 10529398
Expression, purification, and inhibition of human RET tyrosine kinase.
Mologni L, Sala E, Riva B, Cesaro L, Cazzaniga S, Redaelli S, Marin O, Pasquato N, Donella-Deana A, Gambacorti-Passerini C. Mologni L, et al. Protein Expr Purif. 2005 May;41(1):177-85. doi: 10.1016/j.pep.2005.01.002. Protein Expr Purif. 2005. PMID: 15802236
Gene expression analysis fails to identify patients with chronic myeloid leukemia who will achieve cytogenetic response to imatinib.
Gambacorti-Passerini C. Gambacorti-Passerini C. Haematologica. 2005 Apr;90(4):434. Haematologica. 2005. PMID: 15820927 No abstract available.
SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling.
Coluccia AM, Benati D, Dekhil H, De Filippo A, Lan C, Gambacorti-Passerini C. Coluccia AM, et al. Cancer Res. 2006 Feb 15;66(4):2279-86. doi: 10.1158/0008-5472.CAN-05-2057. Cancer Res. 2006. PMID: 16489032
Inhibition of RET tyrosine kinase by SU5416.
Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M, Bain J, Cleris L, Redaelli S, Riva B, Formelli F, Scapozza L, Gambacorti-Passerini C. Mologni L, et al. J Mol Endocrinol. 2006 Oct;37(2):199-212. doi: 10.1677/jme.1.01999. J Mol Endocrinol. 2006. PMID: 17032739
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti-Passerini C. Puttini M, et al. Cancer Res. 2006 Dec 1;66(23):11314-22. doi: 10.1158/0008-5472.CAN-06-1199. Epub 2006 Nov 17. Cancer Res. 2006. PMID: 17114238
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
Coluccia AM, Vacca A, Duñach M, Mologni L, Redaelli S, Bustos VH, Benati D, Pinna LA, Gambacorti-Passerini C. Coluccia AM, et al. EMBO J. 2007 Mar 7;26(5):1456-66. doi: 10.1038/sj.emboj.7601485. Epub 2007 Feb 22. EMBO J. 2007. PMID: 17318191 Free PMC article.
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy.
Gunby RH, Sala E, Tartari CJ, Puttini M, Gambacorti-Passerini C, Mologni L. Gunby RH, et al. Anticancer Agents Med Chem. 2007 Nov;7(6):594-611. doi: 10.2174/187152007784111340. Anticancer Agents Med Chem. 2007. PMID: 18045055 Review.
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.
Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C. Sala E, et al. Mol Cancer Res. 2008 May;6(5):751-9. doi: 10.1158/1541-7786.MCR-07-2001. Epub 2008 May 5. Mol Cancer Res. 2008. PMID: 18458053
277 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback